Atlab Pharma

Targeted radiotherapy of cancer

Project Description

Developing a radio-antibody delivering radioactive particles in the disseminated tumor cells in the body

Its flagship Phase II product is already tested on over 175 patients

Very important survival gain potential for patients with metastatic prostate cancer. In particular higher than the Xofigo® (Sales USD 300m)

Dr. Jean-Marc LE DOUSSAL
Founder & CEO

Immunologist and serial entrepreneur with over 20 years experience in the creation and development of startup

Project Details

Back to Top